BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Here are 10 stores where you can get a free Thanksgiving turkey - 25 Breakout Stars in Late television Series
- 3Taylor Swift changes 2 song lyrics on 'Reputation' on the night of her Eras tour documentary premiere
- 4Staggering Spots to Stargaze All over the Planet
- 5$2,000 tariff rebate checks? 50-year mortgages? Making sense of Trump's new 'affordability' proposals.
- Scientists document a death from a meat allergy tied to certain ticks
- The most effective method to Oversee Unsold SUVs in the Car Business
- Instructions to Pick the Right Dental Expert for Teeth Substitution
- European Travel Objections for 2024
- The Solution to Defeating Tarrying: Systems for Expanded Efficiency
- Get To Be familiar with The Historical backdrop Of Western Medication
- Choosing the Ideal Bed for Quality Rest and Solace
- Manual for Savvy Home Lighting Framework: Lights up Your Space
- Home Plan Tips for Seniors
